Merck Reports P-III (MK-8591A-052 & MK-8591A-051) Trial Data of Doravirine + Islatravir (DOR/ISL) for HIV-1 Infection in Adults
Shots: Merck has reported 2 P-III (
Arvinas & Pfizer Reports Topline Data from P-III (VERITAC-2) Trial of Vepdegestrant for Breast Cancer
Shots: Arvinas & Pfizer have reported topline data from ongoing P-III (
Novo Nordisk Reveals P-III (REDEFINE 2) Trial data of CagriSema for Weight Loss in Obese/Overweight and T2D Patients
Shots: Novo Nordisk has reported P-III (REDEFINE 2) trial data assessing CagriSema...
Johnson & Johnson Highlights P-III Clinical Data of Icotrokinra for Plaque Psoriasis at AAD 2025
Shots: J&J has reported P-III trial data incl. ICONIC-LEAD (vs PBO) & ICON...
Incyte Highlights P-III (TRuE-PN) Clinical Program Data of Opzelura (1.5% Ruxolitinib Cream) for Prurigo Nodularis (PN) at AAD 202...
Shots: Incyte has reported P-III (TRuE-PN:
